Author

Deepa Waghray

Stanford Medicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biophysics· 1 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Approach:deep learning· 1

Frequent Co-Authors

K. Christopher GarcíaiD· 3 shared Hua JiangiD· 2 shared Kevin M. JudeiD· 2 shared Leon SuiD· 2 shared Aastha PaliD· 1 shared Ada WongiD· 1 shared Ansuman T. SatpathyiD· 1 shared Anusha K. KalbasiiD· 1 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBiophysics

K. Christopher GarcíaORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Structural basis of stepwise G protein activation by the viral chemokine receptor US28

Kevin M. Jude, Carl‐Mikael Suomivuori, Deepa Waghray, Shoji Maeda, Yoshinori Fujiyoshi, Asuka Inoue, K. Christopher García, Naotaka Tsutsumi

The paper determines structural states of the US28-Gq complex to elucidate a stepwise G protein activation mechanism.

Nature Communications · Sep 28, 2026Peer-reviewedBiophysics

T cell engagers control solid tumors through clonal replacement and IL2-driven effector differentiation of CD8 T-cells

Matthias Obenaus, Clara L. Poupault, Christopher S. McGinnis, Céline Jasmin Prange, Hua Jiang, Leon Su, Xiaojing Tina Chen, Zhuang Miao, Joseph J. Muldoon, Winnie Yao, Deepa Waghray, Qinli Sun, Justin Eyquem, Rogelio Antonio Hernández-López, Ansuman T. Satpathy, , K. Christopher García

Combining TCE therapy with IL-2 enhances TCE efficacy in aggressive small-cell lung cancer and melanoma models with low target antigen density through T cell clonal replacement and CD8+ effector T cell differentiation.

bioRxiv · Jan 27, 2026 · PreprintCancer Biology

IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy

Hua Jiang, Sam P. Limsuwannarot, Kayla R. Kulhanek, Aastha Pal, Ossama Labiad, Lea Wenting Rysavy, Ada Wong, Leon Su, Sarah M. Cavender, Johnathon Soro, Stefano Testa, Heather Anne N. Ogana, Deepa Waghray, Pingdong Tao, Kevin M. Jude, , Anusha K. Kalbasi

The paper shows that T cells engineered with IL-9R have better tissue infiltration, stemness, and anti-tumor activity compared to those with an orthogonal IL-9 receptor, due to stronger and more specific JAK/STAT signaling.

Immunity · Nov 21, 2025Peer-reviewedImmunology